Veranstaltungen

DKF Tag der Klinischen Forschung, Universitätsspital Basel, 10.2.2022.

Abstract/Poster:
ENGOT-ov54/Swiss-GO-2/MATAO: MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer - A Swiss investigator initiated RCT on re-purposing of a generic drug.

Presenter: Pamela McLaughlin

Aktuell: Annemarie Karrasch Forschungspreis: Preisverleihung 2022 Prof. Dr. Viola Heinzelmann-Schwarz

MATAO CH-D-A Investigator (PI) Meeting, Basel 5.-6- März 2022 (virtuell)

SAKK In-between Meeting I: 10.03.2022, 16.00-18.00h (virtuell)

AACR Annual Meeting, 8.4.-13.4.2022 (New Orleans, USA), Abstract submission closed / None submitted

SAKK Semi-Annual Meeting: 05.05.–06.05.2022 in Zürich (finale Entscheidung nicht vor dem 5. bzw 6.Mai 2022)

• Swiss-GO Mitgliederversammlung (geplant Anfang Juni)
• ASCO Annual Meeting 2022, 3.6-7.6.2022 (Chicago, USA), Abstract submission deadline: 15.02.2022
• SGGG Jahresversammlung, 23.6.-25.6.2022 (St.Gallen), Abstract-Einreichungsfrist: 10.02.2022 (17 Uhr)

Aktuell: Podcast Episode mit Prof. Viola Heinzelmann in der Podcast Serie  "Wissen gegen Krebs" von und mit der Krebsforschung Schweiz: "Unabhängige Forschung – der Schlüssel zu Innovation"

• DGGG, 64. Jahresversammlung, 12.10.-15.10.2022 (München), Abstract-Einreichungsfrist: 15.05.2022
• ENGOT Assembly 6.- 7. Oktober 2022 in Berlin

SAKK : Semi-Annual Meeting II 16.11.2022,Congress Center Basel, Messeplatz 21, 4058 Basel, 13.30-17h

Konferenzen

• Festival of Biologics:   World Clinical Trials Congress Basel 2022  November 2nd, 2022 
  Panel discussion : "Panel Discussion: How has the pandemic redefined decentralized clinical trials?" 
  Speakers: Pamela Mclaughlin, Clinical Trial Manager at Swiss GO Trial Group and Clinical Chemist,University Hospital Basel, Laura Galuchie,Sr Director, Global Trial Management, MSD and Benoit Marchal, Project Manager, Partners for patients
• ASCO Annual Meeting 2021, 4.6.-8.6.2021 (Chicago, USA)

Abstract/Poster:
ENGOT-ov54/Swiss-GO-2/MATAO including LOGOS (Low Grade Ovarian cancer Sub-study): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer; a randomized, double-blinded, placebo-controlled, multi-center phase III Trial
Viola A. Heinzelmann-Schwarz, Christian Kurzeder, Seraina Schmid, Natalie Gabriel, Andreas Mueller, Mathias K. Fehr, Christian Marth, Andreas Du Bois, Maximillian Klar

• ASCO Annual Meeting 2021, 4.6.-8.6.2021 (Chicago, USA)

Abstract/Poster:
Health concerns in long-term survivors with ovarian cancer: Results of Expression VI–Carolin meets HANNA–Holistic Analysis of Long-term survival with Ovarian Cancer—The international NOGGO, ENGOT and GCIG survey
Hannah Woopen, Maren Keller, Ioana Braicu, Dario Zocholl, Joanna Baum, Petra Krabisch, Tamara Boxler, Pauline Wimberger, Catarina Madroñal, Marta Gil-Martin, Vesna Bjelic-Radisic, Sinisha Trpchevski, Eleftherios Pierre Samartzis, Viola A. Heinzelmann-Schwarz, Patriciu Achimaș-Cadariu, Paul Kubelac, Mehmet Ali Vardar, Marcin Andrzej Jedryka, Ignace Vergote, Jalid Sehouli

• ENGOT Meeting 2021, 30.9-1.10. 2021 (Kopenhagen, DK)

Abstract:
ENGOT-ov54/Swiss-GO-2/MATAO including LOGOS (Low Grade Ovarian cancer Sub-study): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer; a randomized, double-blinded, placebo-controlled, multi-center phase III Trial
Viola A. Heinzelmann-Schwarz, Christian Kurzeder, Seraina Schmid, Natalie Gabriel, Andreas Mueller, Mathias K. Fehr, Christian Marth, Andreas Du Bois, Maximillian Klar

• GCIG Autumn Meeting 2021, 8.11.-19.11.2021 (virtual)

Abstract:
ENGOT-ov54/Swiss-GO-2/MATAO including LOGOS (Low Grade Ovarian cancer Sub-study): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer; a randomized, double-blinded, placebo-controlled, multi-center phase III Trial
Viola A. Heinzelmann-Schwarz, Christian Kurzeder, Seraina Schmid, Natalie Gabriel, Andreas Mueller, Mathias K. Fehr, Christian Marth, Andreas Du Bois, Maximillian Klar